Cadrenal Therapeutics, Inc. (CVKD) stock
Close on Nov 13, 2026Market cap $5.39MP/E –Yield 1092.72%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.32
- Dividend yield
- 1092.72%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.54M
- EPS, diluted
- -$4.92
- Free cash flow
- -$12.61M
- Book value per share
- $1.40
- Diluted shares
- 3M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.51
- Open
- $1.49
- Day's range
- $1.43 – $1.56
- Volume
- 42,092
- Average volume (20 days)
- 97,677
- Beta (5 years)
- 1.31
- 52-week range
- $0.82 – $12.50
- RSI (14 days)
- 71.5
- Volatility (1 year)
- 109.2%
- Relative volume
- 0.12×
- WACC
- 11.6%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CVKD | S&P 500 | Difference | CVKD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +51.5% | -3.0% | +54.5 pts | ||
| 3 months | -18.8% | -2.8% | −16.0 pts | ||
| Year to date | -77.7% | +11.5% | −89.2 pts | ||
| 1 year | -87.0% | +13.5% | −100.5 pts | ||
| 3 years | -75.4% | +77.7% | −153.1 pts | -37.4% | +21.1% |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cadrenal Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- News
- Update
About Cadrenal Therapeutics
Pharmaceutical Preparations
Cadrenal Therapeutics, Inc. is a biopharmaceutical company that develops therapies for life-threatening immune and thrombotic conditions. Its lead drug candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor evaluated for the treatment and prevention of heparin-induced thrombocytopenia. The company's pipeline also includes tecarfarin, an oral vitamin K antagonist intended for patients with end-stage kidney disease and atrial fibrillation or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute hospital care. The company focuses on patient populations with complex anticoagulation requirements and high thrombotic risks.
Company profile, executives and historyCadrenal Therapeutics stock: common questions
What is Cadrenal Therapeutics's stock price?
CVKD closed at $1.51 on Nov 13, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $0.82 and $12.50.
What is Cadrenal Therapeutics's market cap?
Cadrenal Therapeutics was worth $5.39M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CVKD's P/E ratio?
Cadrenal Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.92), so it has no meaningful P/E ratio.
Does Cadrenal Therapeutics pay a dividend?
Yes. Cadrenal Therapeutics paid $16.50 per share over the last twelve months, a yield of 1092.72% at the latest price.
When does Cadrenal Therapeutics report earnings next?
Cadrenal Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has CVKD stock performed over the past year?
Including dividends, CVKD returned -87.0% over the past year, against +13.5% for the S&P 500.
How many CVKD shares are sold short?
0M shares were sold short at the latest FINRA report, 9.45% of the float, or 3.5 days of average trading volume.
Who are Cadrenal Therapeutics's competitors?
Companies most similar to Cadrenal Therapeutics by business, industry and size include TLPH, TENX, LGVN, SCNX, VERA.
See a number that looks wrong?